Thiamine for Wernicke-Korsakoff Syndrome

Table of Contents

1. What Wernicke-Korsakoff Syndrome Is
2. The Biochemistry of Thiamine Deficiency in the Brain
3. At-Risk Populations
4. The Classical Triad and Why It Is Often Incomplete
5. Caine Diagnostic Criteria
6. Magnetic Resonance Imaging Findings and Mammillary Body Atrophy
7. Wernicke Encephalopathy vs Korsakoff Syndrome
8. Emergency Treatment Protocol
9. Oral Thiamine in Acute Treatment: The 5 mg Claim and the Measurements
10. The Glucose-Before-Thiamine Trap
11. Bariatric Surgery and Refeeding Syndrome
12. Prognosis and Long-Term Management
13. Cautions
14. Key Research Papers
15. Connections
16. Featured Videos

What Wernicke-Korsakoff Syndrome Is

Wernicke-Korsakoff syndrome (WKS) is the name given to the two sequential clinical phases produced by severe thiamine deficiency affecting the brain. Wernicke encephalopathy is the acute, hyperacute, or subacute phase — an emergency that, with prompt parenteral thiamine, is at least partly reversible. Korsakoff syndrome is the chronic residual phase that develops in patients who survive Wernicke encephalopathy but were not treated rapidly enough — it is a profound, permanent, anterograde amnestic dementia, often with confabulation, that ends most patients' ability to live independently.

The condition was originally described in three populations — chronic alcoholics, prisoners of war on starvation diets, and patients with persistent vomiting. The historical name "polioencephalitis hemorrhagica superior" reflects the punctate hemorrhages found at autopsy in the periaqueductal gray, mammillary bodies, and walls of the third and fourth ventricles — all watershed regions of high oxidative demand that fail first when TPP-dependent enzymes can no longer turn pyruvate into acetyl-CoA.

The mortality of untreated Wernicke encephalopathy is approximately 17-20%. Of survivors who were not treated within 48-72 hours, roughly 80% develop Korsakoff syndrome and require long-term institutional care. These are widely quoted figures, and this page holds no primary study for the 48-72 hour condition. A 2026 review states that mortality approaches 20% in untreated cases. A 2017 critical review notes that the commonly quoted progression figure of 84% comes from one old case series that required the full triad, so it favored severe cases, and it was not meant as a general rate; a later study it cites found 56%. Conversely, when parenteral thiamine is given within hours of presentation, ocular signs typically resolve within 24-48 hours, ataxia improves over days to weeks, and confusion clears over days to months — with a substantial minority of patients returning to near-normal function.

Wernicke-Korsakoff syndrome therefore has the unusual property of being both a catastrophic, dementia-producing illness and one of the most treatable neurological emergencies in modern medicine — the determining variable is not the severity of the deficiency but the speed of parenteral thiamine administration.

Back to Table of Contents

The Biochemistry of Thiamine Deficiency in the Brain

Three key enzymes in human metabolism require thiamine pyrophosphate (TPP) as a cofactor (a fourth, branched-chain 2-oxo acid dehydrogenase, also uses it):

1. Pyruvate dehydrogenase (PDH) — converts pyruvate to acetyl-CoA, the irreversible bridge between glycolysis and the Krebs cycle.
2. α-Ketoglutarate dehydrogenase (α-KGDH) — the rate-limiting enzyme of the Krebs cycle itself.
3. Transketolase — the bridging enzyme of the pentose phosphate pathway, generating reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate.

When TPP becomes scarce, all three enzymes lose activity in proportion to the deficit. The brain is uniquely vulnerable for three reasons. First, it consumes glucose as its almost-exclusive fuel and has no significant capacity to oxidize fatty acids — so blocked PDH directly starves the brain of acetyl-CoA. Second, the brain has the highest oxidative demand per gram of any tissue, so α-KGDH inhibition collapses adenosine triphosphate (ATP) supply rapidly. Third, certain brain regions (mammillary bodies, periaqueductal gray, dorsomedial thalamus, walls of the third and fourth ventricles) lie at the watershed between cerebral vascular territories and receive marginal oxygen and glucose delivery even in health — they fail first when energy production crashes.

The biochemical fingerprint of acute thiamine deficiency is lactic acidosis: with PDH inhibited, pyruvate cannot enter the Krebs cycle and is shunted to lactate by lactate dehydrogenase. A malnourished, confused, ataxic patient with an unexplained metabolic acidosis and a high lactate is Wernicke encephalopathy until proven otherwise. The lactate often falls rapidly with parenteral thiamine — the response to treatment itself is diagnostic.

Glutamate excitotoxicity is the proposed mechanism of the cellular damage. With adenosine triphosphate supply impaired, the Na+/K+ ATPase and glutamate-reuptake pumps fail, glutamate accumulates in the synaptic cleft, N-methyl-D-aspartate (NMDA) receptors fire continuously, calcium floods into neurons, and apoptotic cascades engage. This is why prolonged Wernicke encephalopathy converts to Korsakoff syndrome — the neurons die. Earlier intervention preserves more neurons; the time window matters.

Back to Table of Contents

At-Risk Populations

The classical at-risk population is the chronic alcoholic — alcohol impairs thiamine absorption from the small intestine, accelerates urinary thiamine loss, depletes liver stores, replaces calorically-dense food with empty ethanol calories, and is often paired with the dietary chaos of severe alcohol use disorder. In high-income countries, alcoholism is still the dominant cause of Wernicke-Korsakoff syndrome by a wide margin.

But the at-risk list extends far beyond alcoholism, and a number of newer causes have emerged that physicians who trained before 2000 often fail to recognize:

• Bariatric surgery — Roux-en-Y gastric bypass and sleeve gastrectomy patients can develop Wernicke encephalopathy within weeks of surgery, particularly if they vomit persistently or do not take their prescribed multivitamin. A 2008 systematic review counted 104 reported cases. The combination of bypassed jejunum (where thiamine is absorbed), persistent vomiting, and rapid weight loss without adequate supplementation is the classical setup.
• Hyperemesis gravidarum — pregnant women with intractable vomiting during the first trimester. Wernicke encephalopathy in pregnancy has been reported many times and the consequences for both mother and fetus are devastating when missed. A 2006 review of 49 cases emphasizes thiamine supplementation for women with prolonged vomiting in pregnancy, especially before intravenous or parenteral nutrition, and prompt replacement when neurologic signs develop.
• Prolonged parenteral nutrition without thiamine supplementation — in 1988 and 1989, intravenous multivitamins were briefly removed from intravenous feeding (total parenteral nutrition, TPN) bags due to a shortage in the United States, and a cluster of deaths from acute beriberi and Wernicke encephalopathy followed within weeks. The lesson was learned, but the trap recurs sporadically when generic intravenous feeding is mixed without standard additives. A later shortage is documented: in 1997 the Centers for Disease Control and Prevention (CDC) reported a nationwide shortage of intravenous multivitamins since November 1996 and described three patients on intravenous feeding with thiamine-deficiency lactic acidosis.
• Refeeding syndrome — when a severely malnourished patient (anorexia nervosa, prolonged starvation, post-incarceration, post-famine, prolonged intensive care unit (ICU) stay) is refed with carbohydrate, glucose suddenly drives aggressive cellular uptake of phosphate, magnesium, and thiamine. Pre-existing borderline thiamine status can collapse acutely. The UK NICE guideline CG32 lists oral thiamine 200 to 300 mg daily immediately before and during the first 10 days of feeding (or a full-dose daily intravenous vitamin B preparation, if necessary).
• Gastrointestinal (GI) cancers and malabsorption syndromes — gastric cancer, esophageal cancer, severe Crohn's, short-bowel syndrome, untreated celiac disease — any condition that produces sustained reduced intake combined with malabsorption.
• Chronic hemodialysis — thiamine is dialyzed out of plasma during each session. Dialysis patients who eat poorly are at chronic risk and case series of beriberi and Wernicke encephalopathy in dialysis populations are well documented.
• Cancer patients on chemotherapy with persistent vomiting — particularly with regimens like high-dose cisplatin and stem cell transplant conditioning.
• The homeless and severely mentally ill — chronic undernutrition without alcohol can be enough.

The unifying feature is sustained reduced effective thiamine intake (whether from poor diet, vomiting, malabsorption, surgical bypass, dialysis, or accelerated demand) for more than 2-4 weeks. Body stores of thiamine are only 30-50 mg total, with a half-life of roughly 10-20 days — so the time window from adequate to deficient is measured in weeks, not months.

Back to Table of Contents

The Classical Triad and Why It Is Often Incomplete

The classical triad of Wernicke encephalopathy is:

1. Ophthalmoplegia — horizontal nystagmus first, then lateral rectus weakness (sixth nerve palsy), then more extensive ophthalmoplegia. Diplopia, blurred vision, and abnormal pupillary responses can also occur. The brainstem oculomotor nuclei sit in the periaqueductal gray and are among the first regions to fail.
2. Ataxia — truncal and gait ataxia, often profound, reflecting cerebellar vermis involvement. Patients cannot stand without support.
3. Global confusion / encephalopathy — disorientation, drowsiness, inattention, sometimes progressing to coma. Hallucinations and agitation can occur.

The single most important clinical fact about the classical triad is that it is present in only 10-16% of patients who turn out to have Wernicke encephalopathy on autopsy. The disease is dramatically underdiagnosed because clinicians wait for the complete triad before treating. Modern criteria (Caine 1997, see next section) explicitly allow diagnosis based on any two of four features, precisely to address this underdiagnosis.

The numbers behind this come from autopsy work. In a 1986 study of 131 cases diagnosed at autopsy, 80% had not been diagnosed during life, only 16% had the full triad and 19% had no recorded signs at all. The picture differs by setting: in a 2006 review of 49 cases in pregnancy, the triad appeared in 46.9%, complete remission occurred in only 14 of the 49, and pregnancy was lost in 47.9%.

Other clinical features that raise suspicion include hypothermia (the hypothalamus is affected), hypotension and tachycardia, peripheral neuropathy (which usually coexists), and any combination of malnutrition risk factors with new neurological signs.

Back to Table of Contents

Caine Diagnostic Criteria

The 1997 Caine operational criteria are the modern bedside standard. They were built and tested in people with alcohol use disorder (106 alcoholics screened from a large autopsy sample) and have since been applied more widely, for example in a 2008 review of cases after bariatric surgery; the EFNS guideline adds that the different presentations in people who do not drink are taken into account. They diagnose Wernicke encephalopathy when two of the following four are present:

1. Dietary deficiency — any evidence of inadequate intake, malabsorption, vomiting, or alcohol use sufficient to plausibly deplete thiamine stores.
2. Oculomotor abnormalities — nystagmus, ophthalmoplegia, or any abnormality of eye movements or pupillary responses.
3. Cerebellar dysfunction — gait ataxia, truncal ataxia, dysmetria, or any objective sign of cerebellar dysfunction.
4. Altered mental state — confusion, drowsiness, memory impairment, or any change from baseline cognition. Mild memory loss alone qualifies.

A 2023 review reports that in the 1997 study sensitivity rose from 23% with the traditional triad to 85% with any two of the revised criteria; the study's own summary reports a high degree of specificity. The EFNS guideline uses them for the diagnosis in people with alcohol use disorder, and they are also described as endorsed by the Royal College of Physicians. The EFNS guideline states that thiamine is indicated for suspected as well as manifest disease and that parenteral thiamine is given to all at-risk people admitted to an emergency room; a 1986 autopsy study also states that parenteral thiamine is given when the diagnosis is suspected. So treatment is commonly started before magnetic resonance imaging (MRI) and before any further workup — the cost of treatment is negligible and the cost of missed diagnosis is permanent dementia or death.

Back to Table of Contents

Magnetic Resonance Imaging Findings and Mammillary Body Atrophy

Magnetic resonance imaging is helpful when available but is not required before initiating treatment — treatment is given on clinical suspicion. The classical magnetic resonance imaging findings of acute Wernicke encephalopathy are symmetric T2 / FLAIR hyperintensities in the medial thalami, periaqueductal gray, mammillary bodies, and dorsal medulla. Contrast enhancement of the mammillary bodies is highly specific. These findings have a sensitivity of approximately 53% and a specificity of 93% for Wernicke encephalopathy, figures from a 1998 study of 15 patients, 15 asymptomatic alcoholics and 15 healthy controls. Its authors call magnetic resonance imaging useful in confirming the diagnosis, and a negative magnetic resonance imaging does not exclude it.

In chronic Korsakoff syndrome, the most characteristic finding is mammillary body atrophy — the mammillary bodies are visibly small or absent on sagittal magnetic resonance imaging, often with associated thalamic atrophy. It supports the diagnosis in the right clinical context, but is not proof on its own: in the same 1998 study, mammillary body shrinkage was seen in 40% of alcoholics with acute Wernicke encephalopathy and 27% of asymptomatic chronic alcoholics, not a significant difference. Frontal atrophy and white matter changes are also commonly seen.

Diffusion-weighted imaging (DWI) can show cytotoxic edema in the affected regions in the very acute phase. These changes generally resolve with treatment, paralleling the clinical improvement.

Back to Table of Contents

Wernicke Encephalopathy vs Korsakoff Syndrome

Roughly 80% of patients who survive untreated or undertreated Wernicke encephalopathy progress to Korsakoff syndrome. The two are best understood as the early and late phases of a single neurochemical lesion, not as separate diseases.

Back to Table of Contents

Emergency Treatment Protocol

No single regimen is proven, and the guidelines differ. The European Federation of Neurological Societies guideline (Galvin 2010) states thiamine 200 mg three times daily, preferably intravenously, before any carbohydrate, and grades this recommendation Level C. The higher-dose regimen below is attributed to the UK Royal College of Physicians (Thomson 2002), as a 2026 review describes it:

• Acute phase: Thiamine 500 mg intravenous three times daily for 2-3 days. Each dose is infused in 100 mL of saline or 5% dextrose over 30 minutes.
• Step-down: Thiamine 250 mg intravenous or into a muscle once daily for at least 5 days more, or until clinical improvement plateaus.
• Maintenance: Thiamine 100 mg orally daily indefinitely (for chronic alcoholics, often for life).
• Alongside: magnesium (often deficient and required for TPP synthesis), other B vitamins, and correction of coexisting electrolyte abnormalities.

The 500 mg intravenous dose is far higher than older protocols (which often used 100 mg) and reflects the recognition that brain TPP repletion is rate-limited by plasma thiamine concentration and that subtoxic doses can still produce dramatic neurological recovery. Anaphylaxis with intravenous thiamine is extremely rare (a commonly quoted estimate is <1 per 5 million doses) and is not treated as a reason to withhold treatment, but observation in a monitored setting during the first dose is standard. The EFNS guideline rates the overall safety of thiamine as very good.

A 2013 Cochrane review found the evidence from randomized trials “insufficient to guide clinicians in determining the dose, frequency, route or duration” of thiamine; a 2014 review states there are “no universally accepted guidelines”; a 2007 review calls the best dose controversial.

Randomized dose trials have since been run. In Australian patients with alcohol misuse, reported in 2022, 393 at-risk people without symptoms received injected thiamine 100 mg daily, 100 mg three times daily or 300 mg three times daily for 3 days, and 127 people with symptoms received 100, 300 or 500 mg three times daily for 5 days. No dose beat another on thinking or on nerve signs. The authors list limitations that temper these results (very unwell patients with other illnesses, and difficulties of testing across cultures), so the trial does not settle the question.

Treatment often falls short in practice. A 2026 scoping review of 26 studies in alcohol-related settings found only two randomized trials of thiamine regimens, no agreement on dose, and diagnostic criteria used inconsistently. Prescribing audits it gathered consistently reported undertreatment, including delayed treatment and frequent use of oral thiamine in high-risk situations.

Clinical response is rapid when it occurs. Ocular signs improve within hours to 24 hours. Confusion typically begins to clear within 24-72 hours. Ataxia improves over days to weeks. Memory deficits (if Korsakoff syndrome has not yet developed) improve over weeks to months — this is the slowest component of recovery and predicts long-term outcome.

Failure of ocular signs to resolve within 48 hours is a poor prognostic sign and suggests Korsakoff syndrome has already developed. Even then, some clinicians give longer-duration parenteral thiamine (extending the 500 mg three-times-daily schedule to 7-10 days) because some degree of recovery may still occur.

Back to Table of Contents

Oral Thiamine in Acute Treatment: The 5 mg Claim and the Measurements

Thiamine absorption from the small intestine is by the active SLC19A2 and SLC19A3 transporters in the jejunum. A long-repeated claim holds that these transporters saturate at approximately 5 mg per single oral dose, so that even when 100 mg or 500 mg of thiamine HCl is taken orally, only about 5 mg is actually absorbed — the rest passing through the gut unchanged and excreted in stool. A 2012 study of single oral doses of 100, 500 and 1,500 mg in healthy people reports otherwise: “high blood levels of thiamine can be achieved rapidly with oral thiamine hydrochloride,” and thiamine “is absorbed by both an active and nonsaturable passive process.”

On the 5 mg claim, oral dosing is far too little, far too slowly, to repair an acutely depleted brain, and plasma thiamine levels achieved with oral 500 mg are said to be roughly 1-5% of those achieved with parenteral 500 mg. The 2012 measurements were made in healthy volunteers, not in people acutely ill. In an alcoholic patient with disrupted gastrointestinal absorption and a malnourished gut mucosa, oral absorption is reduced even further.

The guidelines favor injection in the acute illness: the EFNS guideline states “preferably intravenously” and parenteral thiamine for at-risk emergency admissions. The common teaching goes further: oral thiamine has no role in the acute treatment of Wernicke encephalopathy and is appropriate only for long-term maintenance after acute repletion has been achieved with parenteral thiamine. It is also claimed that hospital protocols that allow oral-only thiamine for at-risk patients are negligent by current standards; this page holds no legal source for that.

The fat-soluble thiamine derivatives — allithiamine, sulbutiamine and fursultiamine (thiamine tetrahydrofurfuryl disulfide, TTFD) — cross the gut by passive diffusion and achieve plasma levels 5-25× higher than thiamine HCl at equivalent doses. Benfotiamine is often grouped with them but differs: a 2008 study describes it as practically insoluble in water, organic solvents or oil, and proposes that it is absorbed only after intestinal enzymes remove its phosphate. These derivatives are useful for long-term oral maintenance and for chronic conditions like diabetic neuropathy, but even they are described as inadequate for acute Wernicke encephalopathy, where the guidelines name parenteral thiamine.

Back to Table of Contents

The Glucose-Before-Thiamine Trap

An iconic teaching in emergency medicine is that intravenous glucose given to a malnourished patient before thiamine can precipitate Wernicke encephalopathy. The mechanism: glucose loading drives aggressive cellular utilization of any remaining thiamine to phosphorylate the influx of glucose-derived pyruvate, exhausting the marginal reserves, and the thiamine-dependent enzymes collapse into the floor. A 2012 literature review of this teaching found 19 papers, none above the level of case reports and case series, and states that true clinical research on the question is lacking.

The EFNS guideline states that thiamine is given before any carbohydrate, and in a 2008 review of 84 cases after bariatric surgery, intravenous glucose without thiamine was a risk factor in 18%. The risk described by the 2012 review is prolonged glucose without added thiamine. Low blood sugar is the exception: that review states that “a delay in giving glucose to hypoglycemic patients cannot be recommended,” with thiamine given promptly after or together with the return to normal blood sugar. Giving thiamine before or with intravenous dextrose in malnourished, alcoholic, or otherwise high-risk patients is now a standard order set on hypoglycemia and altered-mental-status protocols in most hospitals (sometimes called the "banana bag" approach — the yellow-tinted intravenous fluid bag containing thiamine, folate, magnesium, and a multivitamin given to alcoholic patients on admission). The cost of thiamine prophylaxis is roughly $1; the cost of missed Wernicke encephalopathy is incalculable.

The same logic applies to refeeding syndrome — carbohydrate refeeding without thiamine prophylaxis is dangerous in any severely malnourished patient.

Back to Table of Contents

Bariatric Surgery and Refeeding Syndrome

Wernicke encephalopathy after bariatric surgery is now well documented — 104 reported cases in a 2008 systematic review, which concluded that the number is substantially higher than previously reported. The classic timing is 4-12 weeks post-surgery in a patient who has been vomiting persistently (often due to stenosis at the surgical anastomosis) or has been non-compliant with the prescribed multivitamin. Roux-en-Y gastric bypass is the highest-risk procedure because the proximal jejunum (the site of thiamine absorption) is bypassed; sleeve gastrectomy patients are at lower but still meaningful risk.

The clinical presentation can be subtle — a young, otherwise healthy bariatric patient presenting with new gait imbalance, double vision, and "feeling not right" weeks after surgery. The differential diagnosis is wide, but in this context, the EFNS guideline lists parenteral thiamine after bariatric surgery and for at-risk emergency admissions, and it is commonly given before magnetic resonance imaging, before lumbar puncture, before any other workup. The cost is trivial and the benefit is enormous.

Refeeding syndrome is the broader phenomenon: any severely malnourished patient (body mass index (BMI) <16, weight loss of >15% in 3-6 months, minimal nutritional intake for >10 days, low pre-refeed phosphate / magnesium / potassium) is at risk when carbohydrate is reintroduced. The UK NICE guideline CG32 lists oral thiamine 200 to 300 mg daily immediately before and during the first 10 days of feeding (or a full-dose daily intravenous vitamin B preparation, if necessary), alongside slow caloric advancement (starting at a maximum of 10 kcal/kg/day, and only 5 kcal/kg/day in extreme cases) and aggressive electrolyte replacement. Failure to give prophylactic thiamine in this setting has caused deaths.

The list of operations is wider than weight-loss surgery. A 2026 systematic review (13 studies, 1,036 patients) found the condition after cancer and emergency gut operations as well as bariatric surgery. Vomiting was the most common trigger, the classic triad appeared in only a minority, and death rates ranged from 0.3% in bariatric groups to 40% in cancer patients.

Newer weight-loss drugs have joined the list. A 2026 review found six reported cases of Wernicke encephalopathy after semaglutide for obesity, all with prolonged stomach and bowel symptoms and substantial weight loss before the nerve signs; several ended in Korsakoff syndrome or death. A 2026 case report describes Korsakoff syndrome during rapid weight loss on tirzepatide in a 50-year-old man who also had chronic alcohol use disorder. Case reports like these do not show how often this happens.

Back to Table of Contents

Prognosis and Long-Term Management

Prognosis depends almost entirely on speed of treatment. Patients treated within 24-48 hours of symptom onset frequently make substantial or complete neurological recoveries. Patients treated at 5-10 days often develop Korsakoff syndrome to varying degrees. Patients treated beyond 2-3 weeks usually have established Korsakoff with severe permanent amnesia.

For survivors with established Korsakoff syndrome, long-term management focuses on:

• Continued thiamine supplementation — oral 100 mg daily indefinitely, with periodic parenteral boosters in patients with ongoing alcohol use or poor compliance. Some clinicians prefer benfotiamine 300 mg daily for the higher bioavailability. What is not known is how much of it reaches the human brain: in mice, oral benfotiamine raised thiamine in blood and liver but not significantly in the brain, while the same paper describes sulbutiamine as raising thiamine derivatives in the brain.
• Abstinence from alcohol — absolute. Continued drinking accelerates the cognitive decline and adds alcohol-related dementia on top of Korsakoff amnesia.
• Nutritional rehabilitation — adequate protein, calories, and a complete B-complex with magnesium.
• Supportive care — structured environment, memory aids, prompts, and often institutional care, because the anterograde amnesia is profound enough that independent living is rarely possible.
• Family education — the patient's confabulation often misleads family into thinking memory is intact when it is not; explicit education about the nature of Korsakoff amnesia is helpful.

Approximately 25% of Korsakoff patients are commonly said to show meaningful recovery of memory function over months to years if completely abstinent from alcohol and well-nourished; a 2023 review reports that as many as 75% of cases show some degree of improvement over time when treated with high-dose thiamine at admission and staying off alcohol. The remainder plateau at varying degrees of impairment. Mortality in established Korsakoff is elevated, primarily from continued alcohol use, cirrhosis, falls, aspiration, and other complications of severe cognitive impairment.

Back to Table of Contents

Cautions

• Anaphylaxis with intravenous thiamine — extremely rare but reported. A commonly quoted estimate of incidence is <1 per 5 million doses. It is not treated as a reason to withhold treatment; the first dose is commonly given in a monitored setting with resuscitation equipment available.
• Intravenous glucose and thiamine — in malnourished, alcoholic, or high-risk patients the EFNS guideline states thiamine before any carbohydrate. Low blood sugar is the exception: a 2012 review states that glucose is not delayed in hypoglycemia, with thiamine given promptly after or together with the return to normal blood sugar. Giving glucose without thiamine is also claimed to be a standard of care issue with medical-legal weight; this page holds no legal source for that.
• Magnesium replacement is essential — thiamine cannot be converted to TPP without magnesium as a cofactor. Magnesium deficiency causes apparent "thiamine resistance" where parenteral thiamine fails to reverse symptoms.
• Wernicke encephalopathy mimics — central nervous system (CNS) infection, stroke, drug intoxication, hepatic encephalopathy, and posterior reversible encephalopathy syndrome (PRES) can all mimic Wernicke. The EFNS guideline indicates thiamine for suspected disease, so it is commonly given while further workup runs in parallel.
• Refeeding hypophosphatemia and hypomagnesemia in severely malnourished patients can be fatal in the first days of refeeding if not anticipated.
• Bariatric patients with persistent vomiting cannot keep down a multivitamin pill; the EFNS guideline lists parenteral thiamine supplementation after bariatric surgery.
• Pregnant women with hyperemesis — a 2006 review of 49 cases emphasizes thiamine supplementation with prolonged vomiting in pregnancy, especially before intravenous or parenteral nutrition.

Back to Table of Contents

Key Research Papers

1. Caine D et al. (1997). Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. J Neurol Neurosurg Psychiatry. — PubMed PMID: 9010400
2. Thomson AD et al. (2002). The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and emergency department. Alcohol Alcohol. — PubMed PMID: 12414541
3. Galvin R et al. (2010). EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. — PubMed PMID: 20642790
4. Day E et al. (2013). Thiamine for prevention and treatment of Wernicke-Korsakoff syndrome in people who abuse alcohol. Cochrane Database Syst Rev. — PubMed PMID: 23818100
5. Sechi G, Serra A (2007). Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. — PubMed PMID: 17434099
6. Aasheim ET (2008). Wernicke encephalopathy after bariatric surgery: a systematic review. Ann Surg. — PubMed PMID: 18948797
7. Chiossi G et al. (2006). Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet Gynecol Surv. — PubMed PMID: 16551377
8. Donnino MW et al. (2007). Myths and misconceptions of Wernicke's encephalopathy: what every emergency physician should know. Ann Emerg Med. — PubMed PMID: 17681641
9. Centers for Disease Control (1989). Deaths associated with thiamine-deficient total parenteral nutrition. MMWR. — PubMed PMID: 2492074
10. Latt N, Dore G (2014). Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J. — PubMed PMID: 25201422
11. Antunez E et al. (1998). Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. AJR Am J Roentgenol. — PubMed PMID: 9763009
12. Harper C (2009). The neuropathology of alcohol-related brain damage. Alcohol Alcohol. — PubMed PMID: 19147798
13. Smithline HA, Donnino M, Greenblatt DJ (2012). Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin Pharmacol. — PubMed PMID: 22305197
14. Schabelman E, Kuo D (2012). Glucose before thiamine for Wernicke encephalopathy: a literature review. J Emerg Med. — PubMed PMID: 22104258
15. Dingwall KM et al. (2022). What is the optimum thiamine dose to treat or prevent Wernicke's encephalopathy or Wernicke-Korsakoff syndrome? Results of a randomized controlled trial. Alcohol Clin Exp Res. — PubMed PMID: 35428992
16. Goldani AAS et al. (2026). Undertreatment of Wernicke encephalopathy in alcohol-related clinical contexts: a scoping review of diagnosis, thiamine regimens, and clinical management. Addict Sci Clin Pract. — PubMed PMID: 42897605
17. Abu-Qasem H et al. (2026). Wernicke encephalopathy in non-alcoholic patients following gastrointestinal procedures: a systematic review. Front Surg. — PubMed PMID: 42453365
18. Bidesie J, Oudman E (2026). Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence. Obesity (Silver Spring). — PubMed PMID: 42399213
19. Crelier VT et al. (2026). Longitudinal 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) Findings in Korsakoff Syndrome After Rapid Weight Loss During Tirzepatide Therapy: A Case Report. Cureus. — PubMed PMID: 42395251
20. Harper CG, Giles M, Finlay-Jones R (1986). Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry. — PubMed PMID: 3701343
21. Centers for Disease Control and Prevention (1997). Lactic acidosis traced to thiamine deficiency related to nationwide shortage of multivitamins for total parenteral nutrition -- United States, 1997. MMWR Morb Mortal Wkly Rep. — PubMed PMID: 9191033
22. Volvert ML et al. (2008). Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. — PubMed PMID: 18549472
23. Artiukhov AV, Aleshin VA (2025). Covalent Docking to the Active Sites of Thiamine Diphosphate-Dependent Enzymes. Molecules. — PubMed PMID: 41302487
24. Arts NJ, Walvoort SJ, Kessels RP (2017). Korsakoff's syndrome: a critical review. Neuropsychiatr Dis Treat. — PubMed PMID: 29225466
25. Kopelman MD (2023). Observations on the Clinical Features of the Wernicke-Korsakoff Syndrome. J Clin Med. — PubMed PMID: 37834954
26. Batarfi MA (2026). Non-alcoholic Wernicke-Korsakoff Syndrome: A Narrative Review. Saudi J Med Med Sci. — PubMed PMID: 42621645
27. National Institute for Health and Care Excellence. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. Clinical guideline CG32. — NICE CG32 recommendations

PubMed Topic Searches

1. PubMed: Wernicke-Korsakoff thiamine
2. PubMed: Wernicke encephalopathy + bariatric
3. PubMed: Wernicke + hyperemesis gravidarum
4. PubMed: refeeding syndrome + thiamine prophylaxis
5. PubMed: Korsakoff + mammillary atrophy MRI

Back to Table of Contents

Connections

• All Vitamins
• Vitamin B1 Overview
• B1 Benefits Hub
• B1 for Beriberi & Cardiac
• Benfotiamine for Diabetic Neuropathy
• B1 for Cognitive Function & Alzheimer's
• Thiamine and Beriberi
• Thiamine and Brain Health
• Alzheimer's Disease
• Peripheral Neuropathy
• Brain Fog
• Fatigue
• Diabetes
• Magnesium
• Detox Protocols
• ALA for Mitochondria
• Deficiency
• Toxicity
• History
• Sources

Back to Table of Contents

Featured Videos